myasthenia gravis

This Biotech Startup Just Raised $105M to Extinguish Inflammation at the Source

Cour Pharmaceuticals’ nanoparticles reprogram the immune system to stop inflammation behind autoimmune disease. Three big pharma companies joined the startup’s Series A financing, which will fund clinical trials in type 1 diabetes and myasthenia gravis.

By Frank Vinluan

BioPharma, Pharma

Upsized Kyverna IPO Gets $319M to Bring CAR T-Therapy to Autoimmune Diseases

Cell therapies were first validated in cancer, but Kyverna Therapeutics aims to show they’re safe enough for autoimmune diseases. The biotech plans to deploy its IPO cash across clinical trials in lupus nephritis, multiple sclerosis, systemic sclerosis, and myasthenia gravis.

By Frank Vinluan

The Funding Model for Cancer Innovation is Broken — We Can Fix It

Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.

By Eve McDavid - CEO of Mission-Driven Tech